• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Terumo launches therapeutic interventional oncology team

April 13, 2021 By Sean Whooley

TerumoTerumo (TSE: 4543) announced that it has launched a global therapeutic interventional oncology team, effective April 1, 2021.

Leuven, Belgium-based Terumo said in a news release that team’s introduction reflects its aspiration to be a global leader in the interventional oncology space by focusing on improving quality of life and survival.

Team members work in medical strategy, research & development, software development, medical imaging discovery and operations. Laurent Domas, Terumos’ VP of global interventional oncology strategy and therapy development, will lead the team as it develops solutions for people with cancer.

Terumo’s therapeutic interventional oncology portfolio includes drug-eluting microspheres (LifePearl microspheres), selective internal radiation therapy solutions with its Holmium platform (QuiremSpheres microspheres, QuiremScout microsphers and the QSuite software) and thermal microwave ablation with TATO.

Utilizing the new organizational set-up, Terumo plans to accelerate the commercial deployment of these offerings in the EMEA region while expanding the availability of the Holmium platform in other regions, including the U.S. and China. The group will also look to innovate in new, targeted drug-delivery solutions.

“With this team of specialists, we want to provide excellence in developing Interventional Oncology solutions to improve the clinical benefit for patients with cancer, and thus contribute to society through healthcare,” Domas said in the release.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals Tagged With: Terumo Corp.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS